Morgan Stanley’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-151,885
| Closed | -$10.3M | – | 6936 |
|
|
2019
Q3 | $10.3M | Buy |
151,885
+40,139
| +36% | +$2.76M | ﹤0.01% | 2088 |
|
|
2019
Q2 | $6.5M | Buy |
111,746
+52,687
| +89% | +$3.12M | ﹤0.01% | 2638 |
|
|
2019
Q1 | $4.14M | Sell |
59,059
-48,713
| -45% | -$3.61M | ﹤0.01% | 2888 |
|
|
2018
Q4 | $6.94M | Buy |
107,772
+58,920
| +121% | +$4.13M | ﹤0.01% | 2519 |
|
|
2018
Q3 | $3.43M | Sell |
48,852
-7,992
| -14% | -$468K | ﹤0.01% | 3560 |
|
|
2018
Q2 | $2.87M | Sell |
56,844
-36,262
| -39% | -$1.44M | ﹤0.01% | 3746 |
|
|
2018
Q1 | $2.91M | Sell |
93,106
-26,717
| -22% | -$886K | ﹤0.01% | 3628 |
|
|
2017
Q4 | $4.1M | Sell |
119,823
-15,742
| -12% | -$502K | ﹤0.01% | 3317 |
|
|
2017
Q3 | $4.35M | Buy |
135,565
+81,623
| +151% | +$2.57M | ﹤0.01% | 3106 |
|
|
2017
Q2 | $1.76M | Sell |
53,942
-17,796
| -25% | -$564K | ﹤0.01% | 3914 |
|
|
2017
Q1 | $2.26M | Sell |
71,738
-93,504
| -57% | -$2.77M | ﹤0.01% | 3701 |
|
|
2016
Q4 | $4.86M | Buy |
165,242
+104,778
| +173% | +$3.19M | ﹤0.01% | 3024 |
|
|
2016
Q3 | $1.75M | Sell |
60,464
-44,572
| -42% | -$1.24M | ﹤0.01% | 3597 |
|
|
2016
Q2 | $2.72M | Buy |
105,036
+1,582
| +2% | +$42K | ﹤0.01% | 3164 |
|
|
2016
Q1 | $2.56M | Sell |
103,454
-11,980
| -10% | -$329K | ﹤0.01% | 3146 |
|
|
2015
Q4 | $4.06M | Sell |
115,434
-91,052
| -44% | -$2.44M | ﹤0.01% | 2875 |
|
|
2015
Q3 | $4.37M | Buy |
206,486
+75,659
| +58% | +$1.95M | ﹤0.01% | 2775 |
|
|
2015
Q2 | $3.64M | Buy |
130,827
+24,204
| +23% | +$683K | ﹤0.01% | 3082 |
|
|
2015
Q1 | $3.26M | Sell |
106,623
-53,451
| -33% | -$1.7M | ﹤0.01% | 3145 |
|
|
2014
Q4 | $5.12M | Buy |
160,074
+49,966
| +45% | +$1.63M | ﹤0.01% | 2719 |
|
|
2014
Q3 | $3.12M | Buy |
110,108
+8,416
| +8% | +$235K | ﹤0.01% | 3067 |
|
|
2014
Q2 | $2.79M | Buy |
101,692
+27,658
| +37% | +$736K | ﹤0.01% | 3221 |
|
|
2014
Q1 | $1.95M | Sell |
74,034
-83,645
| -53% | -$2.4M | ﹤0.01% | 3440 |
|
|
2013
Q4 | $4.62M | Buy |
157,679
+80,330
| +104% | +$2.55M | ﹤0.01% | 2640 |
|
|
2013
Q3 | $2.37M | Sell |
77,349
-66,499
| -46% | -$2.22M | ﹤0.01% | 3091 |
|
|
2013
Q2 | $4.56M | Buy |
+143,848
| New | +$4.72M | ﹤0.01% | 2418 |
|
Morgan Stanley's GHDX Position: Q4 2019 in Review
Morgan Stanley sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 151,885 shares — an estimated $10.3M sold.
Morgan Stanley first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $10.3M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Morgan Stanley reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Morgan Stanley sold 151,885 Genomic Health, Inc. shares in Q4 2019, an estimated $10.3M.
- Morgan Stanley first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Morgan Stanley's Genomic Health, Inc. position peaked at $10.3M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.